PDCD1 and head and neck squamous cell carcinoma: In 2016, the FDA granted marketing approval for the inaugural class of immune checkpoint inhibitors (ICIs) targeting PD-1, marking a pivotal advancement in treating recurrent head and neck squamous cell carcinoma (HNSCC) (Cohen et al., 2019).